Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Nanoencapsulation of Ruthenium Complex Ru(ThySMet): A Strategy to Improve Selective Cytotoxicity against Breast Tumor Cells in 2D and 3D Culture Models

Author(s): Amanda Blanque Becceneri*, Angelina Maria Fuzer, Ana Carolina Lopes, Patrícia Bento da Silva, Ana Maria Plutin, Alzir Azevedo Batista, Marlus Chorilli and Márcia Regina Cominetti

Volume 21, Issue 2, 2024

Published on: 07 July, 2023

Article ID: e060623217687 Pages: 10

DOI: 10.2174/1570163820666230606110457

Price: $65

Abstract

Background: Ruthenium complexes have shown promise in treating many cancers, including breast cancer. Previous studies of our group have demonstrated the potential of the trans- [Ru(PPh3)2(N,N-dimethylN′-thiophenylthioureato-k2O,S)(bipy)]PF6 complex, the Ru(ThySMet), in the treatment of breast tumor cancers, both in 2D and 3D culture systems. Additionally, this complex presented low toxicity when tested in vivo.

Aims: Improve the Ru(ThySMet) activity by incorporating the complex into a microemulsion (ME) and testing its in vitro effects.

Methods: The ME-incorporated Ru(ThySMet) complex, Ru(ThySMet)ME, was tested for its biological effects in two- (2D) and three-dimensional (3D) cultures using different types of breast cells, MDAMB- 231, MCF-10A, 4T1.13ch5T1, HMT-3522 and Balb/C 3T3 fibroblasts.

Results: An increased selective cytotoxicity of the Ru(ThySMet)ME for tumor cells was found in 2D cell culture, compared with the original complex. This novel compound also changed the shape of tumor cells and inhibited cell migration with more specificity. Additional 3D cell culture tests using the non-neoplastic S1 and the triple-negative invasive T4-2 breast cells have shown that Ru(ThySMet)ME presented increased selective cytotoxicity for tumor cells compared with the 2D results. The morphology assay performed in 3D also revealed its ability to reduce the size of the 3D structures and increase the circularity in T4-2 cells.

Conclusion: These results demonstrate that the Ru(ThySMet)ME is a promising strategy to increase its solubility, delivery, and bioaccumulation in target breast tumors.

Graphical Abstract

[1]
de Freitas E, da Silva P, Chorilli M, et al. Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds. Molecules 2014; 19(5): 5999-6008.
[http://dx.doi.org/10.3390/molecules19055999] [PMID: 24818578]
[2]
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3(1): 16-20.
[http://dx.doi.org/10.1021/nn900002m] [PMID: 19206243]
[3]
Thangavel P, Viswanath B, Kim S. Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors. Int J Nanomedicine 2017; 12: 2749-58.
[4]
Malliappan SP, Kandasamy P, Chidambaram S, Venkatasubbu D, Perumal SK, Sugumaran A. Breast cancer targeted treatment strategies: Promising nanocarrier approaches. Anticancer Agents Med Chem 2020; 20(11): 1300-10.
[http://dx.doi.org/10.2174/1871520619666191022175003] [PMID: 31642415]
[5]
Theochari I, Goulielmaki M, Danino D, Papadimitriou V, Pintzas A, Xenakis A. Drug nanocarriers for cancer chemotherapy based on microemulsions: The case of Vemurafenib analog PLX4720. Colloids Surf B Biointerfaces 2017; 154: 350-6.
[http://dx.doi.org/10.1016/j.colsurfb.2017.03.032] [PMID: 28365424]
[6]
Kumar S, Ranjan Sinha V. Design, development and characterization of topical microemulsions of 5-Fluorouracil for the treatment of non melanoma skin cancer and its precursor lesions. Anticancer Agents Med Chem 2015; 16(2): 259-68.
[http://dx.doi.org/10.2174/1871520615666150907093551] [PMID: 26343142]
[7]
Hungria VTM, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhão RC. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 2004; 53(1): 51-60.
[http://dx.doi.org/10.1007/s00280-003-0692-y] [PMID: 14574458]
[8]
Zhou X, Cao C, Li N, Yuan S. SYL3C aptamer-anchored microemulsion co-loading β-elemene and PTX enhances the treatment of colorectal cancer. Drug Deliv 2019; 26(1): 886-97.
[http://dx.doi.org/10.1080/10717544.2019.1660733] [PMID: 31524012]
[9]
Kanwal U, Irfan Bukhari N, Ovais M, et al. Advances in nano-delivery systems for doxorubicin: An updated insight. J Drug Target 2018; 26(4): 296-310.
[10]
Barenholz YC. Doxil® — The first FDA-approved nano-drug: Lessons learned. J Control Release 2012; 160(2): 117-34.
[http://dx.doi.org/10.1016/j.jconrel.2012.03.020] [PMID: 22484195]
[11]
Naves MA, Graminha AE, Vegas LC, et al. Transport of the ruthenium complex [Ru(GA)(dppe) 2]PF 6 into Triple-Negative breast cancer cells is facilitated by transferrin receptors. Mol Pharm 2019; 16(3): 1167-83.
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b01154] [PMID: 30633527]
[12]
Graminha AE, Honorato J, Dulcey LL, et al. Evaluation of the biological potential of ruthenium(II) complexes with cinnamic acid. J Inorg Biochem 2020; 206: 111021.
[http://dx.doi.org/10.1016/j.jinorgbio.2020.111021] [PMID: 32163810]
[13]
Colina-Vegas L, Oliveira K, Cunha B, Cominetti M, Navarro M, Azevedo Batista A. Anti-proliferative and anti-migration activity of arene-ruthenium(II) complexes with azole therapeutic agents. Inorganics 2018; 6(4): 132.
[http://dx.doi.org/10.3390/inorganics6040132]
[14]
Popolin CP, Reis JPB, Becceneri AB, et al. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. PLoS One 2017; 12(9): e0183275.
[http://dx.doi.org/10.1371/journal.pone.0183275] [PMID: 28898246]
[15]
Lee SY, Kim CY, Nam TG. Ruthenium complexes as anticancer agents: A brief history and perspectives. Drug Des Devel Ther 2020; 14: 5375-92.
[http://dx.doi.org/10.2147/DDDT.S275007]
[16]
Riccardi C, Musumeci D, Trifuoggi M, et al. Anticancer Ruthenium(III) complexes and Ru(III)-containing nanoformulations: An update on the mechanism of action and biological activity. Pharmaceuticals 2019; 12(4): 146.
[17]
Liu J, Lai H, Xiong Z, Chen B, Chen T. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy. Chem Commun 2019; 55(67): 9904-14.
[http://dx.doi.org/10.1039/C9CC04098F] [PMID: 31360938]
[18]
Becceneri AB, Popolin CP, Plutin AM, et al. The trans -[Ru(PPh3)2 (N, N-dimethyl-N′-thiophenylthioureato-k2 O,S)(bipy)]PF6 complex has pro-apoptotic effects on triple negative breast cancer cells and presents low toxicity in vivo. J Inorg Biochem 2018; 186: 70-84.
[http://dx.doi.org/10.1016/j.jinorgbio.2018.05.011] [PMID: 29857173]
[19]
Becceneri AB, Fuzer AM, Plutin AM, Batista AA, Lelièvre SA, Cominetti MR. Three-dimensional cell culture models for metallodrug testing: Induction of apoptosis and phenotypic reversion of breast cancer cells by the trans -[Ru(PPh 3) 2 (N, N -dimethyl- N -thiophenylthioureato-k 2 O,S)(bipy)]PF 6 complex. Inorg Chem Front 2020; 7(16): 2909-19.
[http://dx.doi.org/10.1039/D0QI00502A]
[20]
Zanesco-Fontes I, Silva ACL, da Silva PB, et al. [10]-gingerol-loaded nanoemulsion and its biological effects on triple-negative breast cancer cells. AAPS PharmSciTech 2021; 22(5): 157.
[http://dx.doi.org/10.1208/s12249-021-02006-w] [PMID: 34008089]
[21]
Weaver VM, Howlett AR, Langton-Webster B, Petersen OW, Bissell MJ. The development of a functionally relevant cell culture model of progressive human breast cancer. Semin Cancer Biol 1995; 6(3): 175-84.
[http://dx.doi.org/10.1006/scbi.1995.0021] [PMID: 7495986]
[22]
Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4(4): 359-65.
[http://dx.doi.org/10.1038/nmeth1015] [PMID: 17396127]
[23]
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[24]
Silva P, Souza P, Calixto G, et al. In vitro activity of copper(II) complexes, loaded or unloaded into a nanostructured lipid system, against mycobacterium tuberculosis. Int J Mol Sci 2016; 17(5): 745.
[http://dx.doi.org/10.3390/ijms17050745] [PMID: 27196901]
[25]
Oliveira MB, Calixto G, Graminha M, et al. Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis. Biomed Res Int 2015; 2015: 396894.
[26]
Formariz TP, Chiavacci LA, Scarpa MV, et al. Structure and viscoelastic behavior of pharmaceutical biocompatible anionic microemulsions containing the antitumoral drug compound doxorubicin. Colloids Surf B Biointerfaces 2010; 77(1): 47-53.
[http://dx.doi.org/10.1016/j.colsurfb.2010.01.004] [PMID: 20133113]
[27]
Cunha Júnior AS, Fialho SL, Carneiro LB, Oréfice F. Microemulsões como veículo de drogas para administração ocular tópica. Arq Bras Oftalmol 2003; 66(3): 385-91.
[http://dx.doi.org/10.1590/S0004-27492003000300025]
[28]
Lopalco A, Ali H, Denora N, Rytting E. Oxcarbazepine-loaded polymeric nanoparticles: Development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. Int J Nanomedicine 2015; 10: 1985-96.
[PMID: 25792832]
[29]
Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 1998; 168(2): 221-9.
[http://dx.doi.org/10.1016/S0378-5173(98)00092-1]
[30]
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12(1): 62-76.
[31]
da Silva P, Bonifácio B, Frem R, et al. A nanostructured lipid system as a strategy to improve the in Vitro antibacterial activity of copper(II) complexes. Molecules 2015; 20(12): 22534-45.
[http://dx.doi.org/10.3390/molecules201219822] [PMID: 26694337]
[32]
Guo J, Yu Z, Das M, Huang L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 2020; 14(4): 5075-89.
[http://dx.doi.org/10.1021/acsnano.0c01676] [PMID: 32283007]
[33]
Riccardi C, Musumeci D, Capuozzo A, et al. “Dressing up” an old drug: An aminoacyl lipid for the functionalization of Ru(III)-based anticancer agents. ACS Biomater Sci Eng 2018; 4(1): 163-74.
[http://dx.doi.org/10.1021/acsbiomaterials.7b00547] [PMID: 33418686]
[34]
Leiva MC, Ortiz R, Contreras-Cáceres R, et al. Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. Sci Rep 2017; 7(1): 13506.
[http://dx.doi.org/10.1038/s41598-017-13816-z] [PMID: 29044153]
[35]
Zhang Q, Tian X, Cao X. Transferrin-functionalised microemulsion co-delivery of β-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity. Drug Deliv Transl Res 2019; 9(3): 667-78.
[http://dx.doi.org/10.1007/s13346-019-00623-4] [PMID: 30798476]
[36]
Zhao H, Chen M, Zhao Z, Zhu L, Yuan S. A multicomponent-based microemulsion for boosting ovarian cancer therapy through dual modification with transferrin and SA-R6H4. Drug Deliv Transl Res 2021; 11(5): 1969-82.
[http://dx.doi.org/10.1007/s13346-020-00859-5] [PMID: 33006741]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy